p53 inhibitors are pharmaceutical compounds that inhibit the tumor-suppressing p53 protein, offering potential therapeutic strategies for various types of cancers.

Neuraminidase inhibitors are drugs that target the neuraminidase enzyme, crucial for combating influenza virus infections.

Mcl-1 inhibitors are drugs that target the Mcl-1 protein, crucial for regulating cell survival and apoptosis.

NS5A inhibitors: Revolutionizing hepatitis C treatment with high efficacy and future potential.

Menin inhibitors are drugs that target the menin protein, crucial for regulating gene expression. The future of menin inhibitors is promising, with potential applications in treating various types of cancer.

Nrf2 inhibitors are compounds that target the Nrf2 transcription factor, crucial for defense against oxidative stress.

Myostatin inhibitors are drugs that target myostatin, a protein that regulates muscle growth. The future of myostatin inhibitors is promising, with potential applications in treating muscle-wasting conditions.

mTOR inhibitors are drugs that target the mTOR protein kinase, crucial for regulating cell growth and survival.

MDM2 inhibitors are drugs that target the MDM2 protein, crucial for regulating the tumor suppressor protein p53.

NLRP3 inhibitors are drugs that target the NLRP3 inflammasome, a key player in inflammation and immune responses.

MAO-B inhibitors are drugs that target the MAO-B enzyme, crucial for regulating neurotransmitters like dopamine.

Factor Xa inhibitors are anticoagulant drugs that inhibit Factor Xa, a key enzyme in blood coagulation.